Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pirfenidone.

Literature DB >> 21837822

Pirfenidone.

Luca Richeldi, Uma Yasothan, Peter Kirkpatrick.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2011 PMID： 21837822 DOI： 10.1038/nrd3495

Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694

× No keyword cloud information.

6 in total

1. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters.

Authors: S N Iyer; J S Wild; M J Schiedt; D M Hyde; S B Margolin; S N Giri
Journal: J Lab Clin Med Date: 1995-06

2. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors: Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal: Am J Respir Crit Care Med Date: 2011-03-15 Impact factor: 21.405

3. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Authors: Paul W Noble; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Marilyn K Glassberg; David Kardatzke; Talmadge E King; Lisa Lancaster; Steven A Sahn; Javier Szwarcberg; Dominique Valeyre; Roland M du Bois
Journal: Lancet Date: 2011-05-13 Impact factor: 79.321

4. Pirfenidone in idiopathic pulmonary fibrosis.

Authors: H Taniguchi; M Ebina; Y Kondoh; T Ogura; A Azuma; M Suga; Y Taguchi; H Takahashi; K Nakata; A Sato; M Takeuchi; G Raghu; S Kudoh; T Nukiwa
Journal: Eur Respir J Date: 2009-12-08 Impact factor: 16.671

5. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.

Authors: S N Iyer; G Gurujeyalakshmi; S N Giri
Journal: J Pharmacol Exp Ther Date: 1999-10 Impact factor: 4.030

Review 6. Strategies for treating idiopathic pulmonary fibrosis.

Authors: R M du Bois
Journal: Nat Rev Drug Discov Date: 2010-01-22 Impact factor: 84.694

6 in total

15 in total

1. Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis.

Authors: Satomi Onoue; Yoshiki Seto; Masashi Kato; Yosuke Aoki; Yoshiki Kojo; Shizuo Yamada
Journal: Pharm Res Date: 2013-02-21 Impact factor: 4.200

Review 2. Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.

Authors: Xi Hu; Fan Xia; Jiyoung Lee; Fangyuan Li; Xiaoyang Lu; Xiaozhen Zhuo; Guangjun Nie; Daishun Ling
Journal: Adv Sci (Weinh) Date: 2021-02-12 Impact factor: 16.806

3. Combined Effects of Drugs and Plasticizers on the Properties of Drug Delivery Films.

Authors: Cheryl L Jennings; Thomas D Dziubla; David A Puleo
Journal: J Bioact Compat Polym Date: 2016-06-21 Impact factor: 1.756

4. Pirfenidone ameliorates pulmonary arterial pressure and neointimal remodeling in experimental pulmonary arterial hypertension by suppressing NLRP3 inflammasome activation.

Authors: Emmanouil Mavrogiannis; Quint A J Hagdorn; Venetia Bazioti; Johannes M Douwes; Diederik E Van Der Feen; Silke U Oberdorf-Maass; Marit Westerterp; Rolf M F Berger
Journal: Pulm Circ Date: 2022-07-01 Impact factor: 2.886

5. Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling.

Authors: Yoshiki Seto; Gen Suzuki; Sharon Shui Yee Leung; Hak-Kim Chan; Satomi Onoue
Journal: Pharm Res Date: 2016-03-14 Impact factor: 4.200